A high-throughput Galectin-9 imaging assay for quantifying nanoparticle uptake, endosomal escape and functional RNA delivery

Abstract

RNA-based therapies have great potential to treat many undruggable human diseases. However, their efficacy, in particular for mRNA, remains hampered by poor cellular delivery and limited endosomal escape. Development and optimisation of delivery vectors, such as lipid nanoparticles (LNPs), are impeded by limited screening methods to probe the intracellular processing of LNPs in sufficient detail. We have developed a high-throughput imaging-based endosomal escape assay utilising a Galectin-9 reporter and fluorescently labelled mRNA to probe correlations between nanoparticle-mediated uptake, endosomal escape frequency, and mRNA translation. Furthermore, this assay has been integrated within a screening platform for optimisation of lipid nanoparticle formulations. We show that Galectin-9 recruitment is a robust, quantitative reporter of endosomal escape events induced by different mRNA delivery nanoparticles and small molecules. We identify nanoparticles with superior escape properties and demonstrate cell line variances in endosomal escape response, highlighting the need for fine-tuning of delivery formulations for specific applications.

References 47

1. 1.

   Stein CA, Castanotto D. FDA-approved oligonucleotide therapies in 2017. Mol. Ther. 2017;25:1069-1075.

   Not in our library10.1016/j.ymthe.2017.03.023

2. 2.

   Valeur E, et al. New modalities for challenging targets in drug discovery. Angew. Chem. - Int. Ed. 2017;56:10294-10323.

   Not in our library10.1002/anie.201611914

3. 3.

   Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nat. Biotechnol. 2017;35:222-229.

   Not in our library10.1038/nbt.3802

4. 4.

   Kauffman KJ, Webber MJ, Anderson DG. Materials for non-viral intracellular delivery of messenger RNA therapeutics. J. Control. Release. 2016;240:227-234.

   Not in our library10.1016/j.jconrel.2015.12.032

5. 5.
   Advances in the delivery of RNA therapeutics: from concept to clinical reality · 2017

   No notice
6. 6.

   Gilleron J, et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 2013;31:638-646.

   Not in our library10.1038/nbt.2612

7. 7.

   Wittrup A, et al. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat. Biotechnol. 2015;33:870-876.

   Not in our library10.1038/nbt.3298

8. 8.

   Yonezawa, S., Koide, H. & Asai, T. Recent advances in siRNA delivery mediated by lipid-based nanoparticles. Adv. Drug Deliv. Rev. 10.1016/j.addr.2020.07.022 (2020).

   Not in our library10.1016/j.addr.2020.07.022

9. 9.
   Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo** · 2012

   No notice
10. 10.

    Whitehead KA, et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 2014;5:1-10.

    Not in our library10.1038/ncomms5277

11. 11.

    Paunovska K, et al. Nanoparticles containing oxidized cholesterol deliver mRNA to the liver microenvironment at clinically relevant doses. Adv. Mater. 2019;31:e1807748.

    Not in our library10.1002/adma.201807748

12. 12.
    Naturally-occurring cholesterol analogues in lipid nanoparticles induce polymorphic shape and enhance intracellular delivery of mRNA · 2020

    Corrected
13. 13.

    Zhu X, et al. Surface de-PEGylation controls nanoparticle-mediated siRNA delivery in vitro and in vivo. Theranostics. 2017;7:1990-2002.

    Not in our library10.7150/thno.18136

14. 14.

    Chen D, Parayath N, Ganesh S, Wang W, Amiji M. The role of apolipoprotein and vitronectin-enriched protein corona on lipid nanoparticles for in vivo targeted delivery and transfection of oligonucleotides in murine tumor models. Nanoscale. 2019;11:18806-18824.

    Not in our library10.1039/c9nr05788a

15. 15.

    Kauffman KJ, et al. Optimization of lipid nanoparticle formulations for mRNA delivery in vivo with fractional factorial and definitive screening designs. Nano Lett. 2015;15:7300-7306.

    Not in our library10.1021/acs.nanolett.5b02497

16. 16.

    Smith SA, Selby LI, Johnston APR, Such GK. The endosomal escape of nanoparticles: toward more efficient cellular delivery. Bioconjug. Chem. 2019;30:263-272.

    Not in our library10.1021/acs.bioconjchem.8b00732

17. 17.

    Barondes SH, et al. Galectins: a family of animal β-galactoside-binding lectins. Cell. 1994;76:597-598.

    Not in our library10.1016/0092-8674(94)90498-7

18. 18.

    Paz I, et al. Galectin-3, a marker for vacuole lysis by invasive pathogens. Cell. Microbiol. 2010;12:530-544.

    Not in our library10.1111/j.1462-5822.2009.01415.x

19. 19.

    Delacour D, et al. Apical sorting by galectin-3-dependent glycoprotein clustering. Traffic. 2007;8:379-388.

    Not in our library10.1111/j.1600-0854.2007.00539.x

20. 20.

    Cumpstey I, Salomonsson E, Sundin A, Leffler H, Nilsson UJ. Studies of arginine-arene interactions through synthesis and evaluation of a series of galectin-binding aromatic lactose esters. ChemBioChem. 2007;8:1389-1398.

    Not in our library10.1002/cbic.200700040

21. 21.

    Maier O, Marvin SA, Wodrich H, Campbell EM, Wiethoff CM. Spatiotemporal dynamics of adenovirus membrane rupture and endosomal escape. J. Virol. 2012;86:10821-10828.

    Not in our library10.1128/jvi.01428-12

22. 22.

    Thurston TLM, Wandel MP, von Muhlinen N, Foeglein A, Randow F. Galectin 8 targets damaged vesicles for autophagy to defend cells against bacterial invasion. Nature. 2012;482:414-418.

    Not in our library10.1038/nature10744

23. 23.

    Kilchrist KV, et al. Gal8 visualization of endosome disruption predicts carrier-mediated biologic drug intracellular bioavailability. ACS Nano. 2019;13:1136-1152.

    Not in our library10.1021/acsnano.8b05482

24. 24.
    Imaging small molecule-induced endosomal escape of siRNA · 2020

    No notice
25. 25.

    Maresca M, Lin VG, Guo N, Yang Y. Obligate ligation-gated recombination (ObLiGaRe): custom-designed nuclease-mediated targeted integration through nonhomologous end joining. Genome Res. 2013;23:539-546.

    Not in our library10.1101/gr.145441.112

26. 26.

    Nishi N, Itoh A, Shoji H, Miyanaka H, Nakamura T. Galectin-8 and galectin-9 are novel substrates for thrombin. Glycobiology. 2006;16:15-20.

    Not in our library10.1093/glycob/cwl028

27. 27.

    Bänfer S, Jacob R. Galectins in intra- and extracellular vesicles. Biomolecules. 2020;10:1-12.

    Not in our library10.3390/biom10091232

28. 28.

    Maxfield FR. Weak bases and ionophores rapidly and reversibly raise the ph of endocytic vesicles in cultured mouse fibroblasts. J. Cell Biol. 1982;95:676-681.

    Not in our library10.1083/jcb.95.2.676

29. 29.

    Wang L, et al. A novel family of small molecules that enhance the intracellular delivery and pharmacological effectiveness of antisense and splice switching oligonucleotides. ACS Chem. Biol. 2017;12:1999-2007.

    Not in our library10.1021/acschembio.7b00242

30. 30.

    Yang B, et al. High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res. 2015;43:1987-1996.

    Not in our library10.1093/nar/gkv060

31. 31.

    Chen Z, et al. Mitochondrial E3 ligase MARCH5 regulates FUNDC1 to fine-tune hypoxic mitophagy. EMBO Rep. 2017;18:495-509.

    Not in our library10.15252/embr.201643309

32. 32.

    Hansjosten I, et al. Microscopy-based high-throughput assays enable multi-parametric analysis to assess adverse effects of nanomaterials in various cell lines. Arch. Toxicol. 2018;92:633-649.

    Not in our library10.1007/s00204-017-2106-7

33. 33.

    Iversen PW, Eastwood BJ, Sittampalam GS, Cox KL. A comparison of assay performance measures in screening assays: Signal window, Z′ factor, and assay variability ratio. J. Biomol. Screen. 2006;11:247-252.

    Not in our library10.1177/1087057105285610

34. 34.

    Akinc A, et al. Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms. Mol. Ther. 2010;18:1357-1364.

    Not in our library10.1038/mt.2010.85

35. 35.

    Liu GY, Sabatini DM. mTOR at the nexus of nutrition, growth, ageing and disease. Nat. Rev. Mol. Cell Biol. 2020;21:183-203.

    Not in our library10.1038/s41580-019-0199-y

36. 36.

    Thoreen CC, et al. An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1. J. Biol. Chem. 2009;284:8023-8032.

    Not in our library10.1074/jbc.m900301200

37. 37.

    García-Martínez JM, et al. Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR). Biochem. J. 2009;421:29-42.

    Not in our library10.1042/bj20090489

38. 38.

    Manganiello MJ, Cheng C, Convertine AJ, Bryers JD, Stayton PS. Diblock copolymers with tunable pH transitions for gene delivery. Biomaterials. 2012;33:2301-2309.

    Not in our library10.1016/j.biomaterials.2011.11.019

39. 39.

    Ulkoski, D. et al. High-throughput automation of endosomolytic polymers for mrna delivery. ACS Appl. Bio Mater. acsabm.0c01463 10.1021/acsabm.0c01463 (2021).

    Not in our library10.1021/acsabm.0c01463

40. 40.

    Eygeris, Y., Patel, S., Jozic, A. & Sahay, G. Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery. Nano Lett. acs.nanolett.0c01386 10.1021/acs.nanolett.0c01386 (2020).

    Not in our library10.1021/acs.nanolett.0c01386

41. 41.

    Heyes J, Palmer L, Bremner K, MacLachlan I. Cationic lipid saturation influences intracellular delivery of encapsulated nucleic acids. J. Control. Release. 2005;107:276-287.

    Not in our library10.1016/j.jconrel.2005.06.014

42. 42.

    Semple SC, et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 2010;28:172-176.

    Not in our library10.1038/nbt.1602

43. 43.

    Stetefeld J, McKenna SA, Patel TR. Dynamic light scattering: a practical guide and applications in biomedical sciences. Biophys. Rev. 2016;8:409-427.

    Not in our library10.1007/s12551-016-0218-6

44. 44.

    Van de Vyver T, et al. Cationic amphiphilic drugs boost the lysosomal escape of small nucleic acid therapeutics in a nanocarrier-dependent manner. ACS Nano. 2020;14:4774-4791.

    Not in our library10.1021/acsnano.0c00666

45. 45.

    Joshi BS, de Beer MA, Giepmans BNG, Zuhorn IS. Endocytosis of extracellular vesicles and release of their cargo from endosomes. ACS Nano. 2020;14:4444-4455.

    Not in our library10.1021/acsnano.9b10033

46. 46.

    Castellano BM, et al. Lysosomal cholesterol activates mTORC1 via an SLC38A9-Niemann-Pick C1 signaling complex. Science. 2017;355:1306-1311.

    Not in our library10.1126/science.aag1417

47. 47.

    Sayers EJ, et al. Endocytic profiling of cancer cell models reveals critical factors influencing LNP-mediated mRNA delivery and protein expression. Mol. Ther. 2019;27:1950-1962.

    Not in our library10.1016/j.ymthe.2019.07.018

Reads

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.